Breaking News Instant updates and real-time market news.

ADMS

Adamas Pharmaceuticals

$35.08

-0.39 (-1.10%)

06:02
12/13/17
12/13
06:02
12/13/17
06:02

Adamas Pharmaceuticals named a best idea for 2018 at Cowen

Cowen analyst Ken Cacciatore views shares of Adamas Pharmaceuticals as "meaningfully undervalued" at current levels. He calls the stock a best idea for 2018 and keeps an Outperform rating on the name with a $55 price target. The analyst is confident that Gocovri, which is now on the market, will find a "significant place" in the Parkinson's disease treatment paradigm. He says Adamas has successfully developed an extended release amantadine for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.

ADMS Adamas Pharmaceuticals
$35.08

-0.39 (-1.10%)

10/04/17
PIPR
10/04/17
NO CHANGE
Target $30
PIPR
Overweight
Piper Jaffray stays bullish on Adamas after physician survey
Piper Jaffray analyst David Amsellem says he's staying bullish on Adamas Pharmaceuticals following a "brief survey" of 25 movement disorder specialists. The feedback shows that while there is no consensus, a "significant group" of physicians, even ahead of the launch, view Adamas' Gocovri as a differentiated, potentially valued option for Levodopa-induced dyskinesia patients, Amsellem tells investors in a research note. He continues to believe that peak U.S. sales of at least $200M for the drug are realistic. The analyst reiterates an Overweight rating on Adamas with a $30 price target.
10/25/17
NEED
10/25/17
NO CHANGE
Target $38
NEED
Buy
Adamas FDA orphan exclusivity not a surprise, says Needham
Needham analyst Serge Belanger said it is now a surprise that the FDA granted Adamas seven-years orphan drug exclusivity to Gocovri, or ADS-5102, given that it's in accordance with the FDA's orphan drug designation which was granted to ADS-5102 back in April 2015. Gocovri was FDA approved in August and is expected to become commercially available in November 2017 ahead of a more formal launch in January 2018, the analyst wrote in a note to investors. Belanger said the seven-year exclusivity will allow Adamas to draw-down the $65M tranche from the $100M royalty-backed note. Shares are Buy rated with a $38 price target.
10/30/17
10/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sotheby's (BID) initiated with a Buy at Aegis. 2. Alnylam (ALNY) initiated with a Buy at FBR Capital. 3. Adamas Pharmaceuticals (ADMS) initiated with an Outperform at Evercore ISI. 4. Vipshop (VIPS) initiated with a Neutral at UBS. 5. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/17
NORL
11/29/17
INITIATION
Target $70
NORL
Outperform
Adamas Pharmaceuticals initiated with an Outperform at Northland
Northland analyst Carl Byrnes initiated Adamas Pharmaceuticals with an Outperform and $70 price target. The analyst said Adamas' GOCOVRI is a breakthrough in treating Parkinson's patients that have developed dyskinesia as a result of long-term exposure to levodopa therapy and sees peak sales exceeding $750M.

TODAY'S FREE FLY STORIES

08:40
01/19/18
01/19
08:40
01/19/18
08:40
General news
U.S. equities are in a buoyant mood again »

U.S. equities are in a…

ALB

Albemarle

$117.91

-9.04 (-7.12%)

, SQM

SQM

$59.02

-0.53 (-0.89%)

08:39
01/19/18
01/19
08:39
01/19/18
08:39
Recommendations
Albemarle, SQM, FMC Corporation analyst commentary  »

Albemarle price target…

ALB

Albemarle

$117.91

-9.04 (-7.12%)

SQM

SQM

$59.02

-0.53 (-0.89%)

FMC

FMC Corporation

$90.17

-3.69 (-3.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 28

    Feb

  • 07

    Mar

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

08:38
01/19/18
01/19
08:38
01/19/18
08:38
Hot Stocks
Breaking Hot Stocks news story on Schlumberger »

Schlumberger says will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

CARA

Cara Therapeutics

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Initiation
Cara Therapeutics initiated  »

Cara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMP

Ameriprise

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Recommendations
Ameriprise analyst commentary  »

Ameriprise price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

PCRX

Pacira

$39.10

-1.2 (-2.98%)

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Initiation
Pacira initiated  »

Pacira initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 15

    Feb

  • 06

    Apr

VNDA

Vanda

$14.25

-0.2 (-1.38%)

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Initiation
Vanda initiated  »

Vanda initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

08:36
01/19/18
01/19
08:36
01/19/18
08:36
Hot Stocks
Schlumberger says intends to maintain presence in Venezuela »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

, LGF.B

Lionsgate

$32.84

2.46 (8.10%)

08:34
01/19/18
01/19
08:34
01/19/18
08:34
Recommendations
Lionsgate, Lionsgate analyst commentary  »

Lionsgate price target…

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

LGF.B

Lionsgate

$32.84

2.46 (8.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 08

    Feb

HMNY

Helios and Matheson

$8.14

0.41 (5.30%)

08:32
01/19/18
01/19
08:32
01/19/18
08:32
Hot Stocks
MoviePass announces MoviePass Ventures to co-acquire films »

MoviePass, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$32.75

2.09 (6.82%)

08:32
01/19/18
01/19
08:32
01/19/18
08:32
Recommendations
Ichor Holdings analyst commentary  »

Ichor Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

ABMD

Abiomed

$225.89

1.76 (0.79%)

08:31
01/19/18
01/19
08:31
01/19/18
08:31
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

GTXI

GTx

$12.65

0.15 (1.20%)

08:30
01/19/18
01/19
08:30
01/19/18
08:30
Options
Three new option listings on January 19th »

New option listings for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:30
01/19/18
01/19
08:30
01/19/18
08:30
Hot Stocks
Oramed CEO: Oral GLP-1 analog development is rapidly proceeding »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
SF Fed's Williams is being considered for the Vice Chair spot »

SF Fed's Williams is…

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
Breaking General news story  »

Atlanta Federal Reserve…

AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

08:29
01/19/18
01/19
08:29
01/19/18
08:29
Hot Stocks
AstraZeneca reports Fasenra receives approval in Japan »

AstraZeneca and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

  • 08

    Mar

  • 23

    Apr

SYF

Synchrony

$37.30

-0.76 (-2.00%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Technical Analysis
Technical Take: Synchrony falls after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SM

SM Energy

$25.69

-0.93 (-3.49%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Conference/Events
SM Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

SBNY

Signature Bank

$153.44

5.39 (3.64%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Signature Bank analyst commentary  »

Signature Bank price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$61.84

0.67 (1.10%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$55.60

0.73 (1.33%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Recommendations
Atlassian analyst commentary  »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Hot Stocks
Oramed CEO: 2018 will be an exciting and event driven year »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

, CBG

CBRE Group

$45.19

0.2 (0.44%)

08:26
01/19/18
01/19
08:26
01/19/18
08:26
Conference/Events
Bay Area Council Economic Institute to hold a conference »

11th Annual Forecast…

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

CBG

CBRE Group

$45.19

0.2 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 08

    Feb

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Federal Reserve Bank of San Francisco President speaks at conference »

Federal Reserve Bank of…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.